Trading Report: The Atara Biotherapeutics Inc. (ATRA) Stake Increased by PNC Financial Services Group Inc.

The Atara Biotherapeutics Inc. (ATRA) Stake Increased by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. boosted its stake in Atara Biotherapeutics Inc. (NASDAQ:ATRA) by 6,736.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,563 shares of the company’s stock after buying an additional 6,467 shares during the period. PNC Financial Services Group Inc.’s holdings in Atara Biotherapeutics were worth $148,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. DekaBank Deutsche Girozentrale boosted its position in shares of Atara Biotherapeutics by 23.7% in the second quarter. DekaBank Deutsche Girozentrale now owns 16,200 shares of the company’s stock valued at $365,000 after buying an additional 3,100 shares during the period. California State Teachers Retirement System boosted its position in shares of Atara Biotherapeutics by 35.3% in the second quarter. California State Teachers Retirement System now owns 48,704 shares of the company’s stock valued at $1,096,000 after buying an additional 12,704 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Atara Biotherapeutics by 3.1% in the first quarter. JPMorgan Chase & Co. now owns 62,600 shares of the company’s stock valued at $1,191,000 after buying an additional 1,900 shares during the period. A.R.T. Advisors LLC boosted its position in shares of Atara Biotherapeutics by 79.6% in the first quarter. A.R.T. Advisors LLC now owns 63,941 shares of the company’s stock valued at $1,216,000 after buying an additional 28,330 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Atara Biotherapeutics by 20.9% in the second quarter. Bank of New York Mellon Corp now owns 99,629 shares of the company’s stock valued at $2,243,000 after buying an additional 17,195 shares during the period. 75.50% of the stock is owned by institutional investors and hedge funds.

Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) traded down 1.70% during mid-day trading on Friday, reaching $17.32. 177,896 shares of the company traded hands. Atara Biotherapeutics Inc. has a 52 week low of $13.31 and a 52 week high of $40.80. The firm’s market capitalization is $499.01 million. The firm has a 50-day moving average price of $20.27 and a 200 day moving average price of $20.27.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Monday, August 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.05. On average, analysts anticipate that Atara Biotherapeutics Inc. will post ($2.85) earnings per share for the current year.

Several research analysts have issued reports on the stock. JMP Securities reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a report on Saturday, July 9th. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 2nd. Jefferies Group reaffirmed a “buy” rating and issued a $25.00 target price on shares of Atara Biotherapeutics in a report on Tuesday, August 9th. Goldman Sachs Group Inc. lowered shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $23.00 to $16.00 in a research note on Thursday, September 15th. Finally, Citigroup Inc. lifted their price target on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a “sell” rating in a research note on Friday, August 19th. Three equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $26.14.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 7,200 shares of the stock in a transaction dated Friday, September 16th. The shares were sold at an average price of $19.36, for a total transaction of $139,392.00. Following the completion of the sale, the chief executive officer now directly owns 229,136 shares of the company’s stock, valued at $4,436,072.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Isaac E. Ciechanover sold 9,600 shares of the stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of $22.11, for a total transaction of $212,256.00. Following the sale, the chief executive officer now directly owns 223,228 shares of the company’s stock, valued at $4,935,571.08. The disclosure for this sale can be found here. Company insiders own 16.10% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

Related posts

Leave a Comment